$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Amyloid beta (Aβ) is a peptide of 36-43 amino acids that is formed after sequential cleavage of the amyloid precursor protein (APP) by β and γ secretases 1. The γ secretase processes the C-terminal end of the Aβ peptide and is responsible for its variable lengths 5. The most common forms of Aβ are Aβ40 and Aβ42, the latter being more commonly associated to pathologic conditions such as AD 5. At high concentrations Aβ form β-sheets that aggregate to form amyloid fibrils 6. Fibrils deposits are the main component of senile plaques surrounding neurons. Both plaques and diffusible, non-plaque Aβ oligomers, are thought to constitute the underlying pathogenic forms of Aβ.
Laboratory study of neuronal amylopathies is complicated by the fact that these conditions progress with time. Therefore, it is important to develop genetically tractable animal models-complementary to mice-with short life span. These models can be used to elucidate specific aspects of amylopathies-typically cellular and molecular-and by virtue of their simplicity, help to capture the essence of the problem. The worm Caenorhabditis elegans falls is this category. It has a short life span, ~20 days and in addition basic cellular processes including regulation of gene expression, protein trafficking, neuronal connectivity, synaptogenesis, cell signaling, and death are similar to mammalian 7. Unique features of the worm include powerful genetics and lack of a vessel system, which enables to study neuronal damage independently of vascular damage. On the other hand, the lack of a brain limits the use of C. elegans to studying many aspects of neurodegeneration. In addition, the reproduction and identification of anatomical distributions of lesions cannot be performed in this organism. Other limitations include the difficulty to assess both differences in gene expression profiles and impairment of complex behavior and memory function. Here we describe methods to generate C. elegans models of amylopathies.